The Latest Cardiac and Vascular News
Successfully Met Primary and Secondary Endpoints, with Mean Placebo-Adjusted Reduction in Systolic Blood Pressure of 9.7 mmHg in Uncontrolled and Resistant Hypertensive Subjects at 50 mg Once Daily (p=0.01 vs. placebo) Subjects Using a Thiazide Diuretic (Approximately Half of the Study Population) Showed a Mean Placebo-Adjusted Reduction in Systolic Blood […]
MLS-101 is a Highly Selective Aldosterone Synthase Inhibitor Designed to Address Abnormally Elevated Aldosterone, an Underlying Cause of Hypertension Prevalent in a Significant Portion of Patients Derek DiRocco of RA Capital Management and Olivier Litzka, PhD of Andera Partners Join Mineralys Board of Directors PHILADELPHIA, June 8, 2022 /PRNewswire/ — Mineralys Therapeutics, Inc., a private, […]
PHILADELPHIA, March 15, 2022 /PRNewswire/ — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension, today announced the appointment of Adam Levy as the company’s new Chief Financial Officer (CFO) and Chief Business Officer (CBO). “We are pleased to announce Adam’s appointment and welcome […]
